Loading company…
Suzhou-based Smart Nuclide develops radiopharmaceuticals for cancer diagnosis and treatment at clinical stage.
Based in China and established in 2015, Smart Nuclide is a clinical-stage biopharmaceutical company developing biological drug products for molecular nuclear oncology, including recombinant human thyrotropin, tumor diagnostic radiographic drugs and tumor therapeutic radiopharmaceuticals. In April 2024 it raised approximately CNY 100 million in Series C+ funding. Its plans include launching its human thyrotropin injection and advancing clinical trials of SNA002.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in